| Year |
Citation |
Score |
| 2016 |
Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Research and Treatment. PMID 26860947 DOI: 10.1007/S10549-016-3698-Y |
0.466 |
|
| 2015 |
Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 6: 41123-33. PMID 26516700 DOI: 10.18632/Oncotarget.5660 |
0.488 |
|
| 2015 |
Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular Cancer Therapeutics. 14: 2805-17. PMID 26438156 DOI: 10.1158/1535-7163.Mct-15-0403 |
0.463 |
|
| 2014 |
Park CC, Amin D, Zhang H, Moasser M. Abstract 5438: Resistance to β1 integrin inhibition in HER2 amplified cancers is mediated by HER3 Cancer Research. 74: 5438-5438. DOI: 10.1158/1538-7445.Am2014-5438 |
0.383 |
|
| 2013 |
Amin DN, Ahuja D, Ducker GS, Yaswen P, Shokat K, Moasser M. Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers. Cancer Research. 73: 3043-3043. DOI: 10.1158/1538-7445.Am2013-3043 |
0.517 |
|
| 2012 |
Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. The Biochemical Journal. 447: 417-25. PMID 22853430 DOI: 10.1042/Bj20120724 |
0.479 |
|
| 2010 |
Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Seminars in Cell & Developmental Biology. 21: 944-50. PMID 20816829 DOI: 10.1016/J.Semcdb.2010.08.007 |
0.454 |
|
| 2010 |
Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Research. 70: 3823-32. PMID 20388805 DOI: 10.1158/0008-5472.Can-09-3048 |
0.401 |
|
| 2010 |
Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science Translational Medicine. 2: 16ra7. PMID 20371474 DOI: 10.1126/Scitranslmed.3000389 |
0.543 |
|
| 2010 |
Campbell MR, Amin D, Moasser MM. HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy Clinical Cancer Research. 16: 1373-1383. PMID 20179223 DOI: 10.1158/1078-0432.Ccr-09-1218 |
0.529 |
|
| 2010 |
Amin DN, Sergina N, Ahuja D, McMahon M, Wang D, Hann B, Shokat K, Moasser MM. Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver Cancer Research. 70: 1653-1653. DOI: 10.1158/1538-7445.Am10-1653 |
0.527 |
|
| 2008 |
Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvascular Research. 76: 15-22. PMID 18440031 DOI: 10.1016/J.Mvr.2008.01.002 |
0.481 |
|
| 2006 |
Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Research. 66: 2173-80. PMID 16489018 DOI: 10.1158/0008-5472.Can-05-3387 |
0.495 |
|
| 2005 |
Amin DN, Tuck D, Stern DF. Neuregulin-regulated gene expression in mammary carcinoma cells. Experimental Cell Research. 309: 12-23. PMID 15963498 DOI: 10.1016/J.Yexcr.2005.04.034 |
0.573 |
|
| 2004 |
Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Research. 64: 8249-55. PMID 15548691 DOI: 10.1158/0008-5472.Can-04-1567 |
0.345 |
|
| 2004 |
Amin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene. 23: 1428-38. PMID 14973552 DOI: 10.1038/Sj.Onc.1207257 |
0.564 |
|
| Show low-probability matches. |